Aceto has blamed Aurobindo for its downfall, alleging a series of calculated and deceitful actions that have critically wounded the US group’s pharma business. Aurobindo has strongly denied the charges.
US Aceto Corporation has accused the Indian company Aurobindo Pharma Ltd. of deploying a calculated and systematic scheme to destroy Aceto’s generic pharmaceutical business run through its subsidiary Rising Pharmaceuticals, forcing it out of the US generic market. The Indian group’s actions also allegedly contributed “substantially” to Aceto’s bankruptcy filing.
The case essentially revolves around Aceto’s 2016 acquisition of rights owned by Citron Pharma LLC and its affiliate Lucid Pharma...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
